Key clinical point: Effectiveness of psoriasis treatment with acitretin, etanercept, adalimumab, and secukinumab was not associated with age.
Major finding: Overall, a 75% reduction in the Psoriasis Area and Severity Index was achieved in approximately half or more of psoriasis patients aged 65 years and older who used methotrexate sodium, cyclosporin, acitretin, etanercept, infliximab, adalimumab, ustekinumab, and secukinumab; however, older age was significantly associated with renal failure among patients using cyclosporin and with lymphopenia in those using fumaric acid.
Study details: The data come from a literature review of 31 articles including 39,561 psoriasis patients aged 65 years and older.
Disclosures: The study was supported by Almirall SA (independent research fund of the Department of Dermatology of Radboud University Medical Centre Nijmegen). Lead author Dr. van Winden disclosed relationships with Almirall SA, AbbVie, Celgene, Janssen Pharmaceutica, Leo Pharma, Eli Lilly, and Novartis. Several coauthors disclosed relationships with companies including Almirall SA, Janssen Pharmaceutica, Novartis, and AbbVie.
van Winden MEC et al. JAMA Dermatol.2020 Aug 19. doi: 10.1001/jamadermatol.2020.2311.